A5064378838- Renal cell carcinoma treatment
- Renal and related cancers
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- melanin and skin pigmentation
- RNA regulation and disease
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- CRISPR and Genetic Engineering
- Diagnosis and Treatment of Venous Diseases
- RNA modifications and cancer
- Venous Thromboembolism Diagnosis and Management
- Pancreatic and Hepatic Oncology Research
- Chromatin Remodeling and Cancer
- Cancer-related gene regulation
- Cancer-related Molecular Pathways
- Multiple and Secondary Primary Cancers
- Genetics and Neurodevelopmental Disorders
- Histone Deacetylase Inhibitors Research
- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Urinary and Genital Oncology Studies
Institut de génétique et de biologie moléculaire et cellulaire
2018-2025
Centre National de la Recherche Scientifique
2019-2025
Inserm
2013-2025
Université de Strasbourg
2019-2025
Institut de Cancérologie Strasbourg
2020-2025
Centre Léon Bérard
2024
La Ligue Contre le Cancer
2023
Health First
2022
Hôpitaux Universitaires de Strasbourg
2018-2021
Institut de Biologie Moléculaire et Cellulaire
2018-2021
// Xiaoping Su 1,* , Gabriel G. Malouf 2,* Yunxin Chen 3 Jianping Zhang 1 Hui Yao Vicente Valero John N. Weinstein Jean-Philippe Spano 2 Funda Meric-Bernstam 4 David Khayat and Francisco J. Esteva 5 Departments of Bioinformatics Computational Biology, The University Texas MD Anderson Cancer Center, Houston, TX, USA Groupe Hospitalier Pitié-Salpêtrière, Department Medical Oncology, Pierre Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris,...
Abstract Purpose: MITF/TFE translocation renal cell carcinoma (TRCC) is a rare subtype of kidney cancer. Its incidence and the genome-wide characterization its genetic origin have not been fully elucidated. Experimental Design: We performed RNA exome sequencing on an exploratory set TRCC (n = 7), validated our findings using The Cancer Genome Atlas (TCGA) clear-cell RCC (ccRCC) dataset 460). Results: Using TCGA dataset, we identified seven (1.5%) cases determined their genomic profile....
The epithelial-mesenchymal transition (EMT) imparts metastatic competence on otherwise non-metastatic cancer cells through decreased inter-cellular adhesions, increased migratory capacity, stem cell properties and anoikis chemotherapy resistance. In this study, we profiled changes in microRNA expression during EMT conjunction with DNA methylation at promoters to discover essential mediators of EMT-imparted stemness properties. MicroRNA-203 (miR-203) is repressed following induced by multiple...
Targeting epigenetic pathways is a promising approach for cancer therapy. Here, we report on the unexpected finding that targeting calcium signaling can reverse silencing of tumor suppressor genes (TSG). In screen drugs reactivate silenced gene expression in colon cells, found three classical targeted (DNA methylation and histone deacetylase inhibitors) 11 other induced methylated CpG island promoters driving reporter (GFP) as well endogenous TSGs multiple cell lines. These newly identified...
Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms. Data linking BAF alterations with tumor microenvironment (TME) and efficacy of immune checkpoint inhibitors (ICI) contradictory. The TME SMARCA4-UT their response to ICI unknown.Patients diagnosed in our institution were included. Immunostainings for tertiary lymphoid structures (TLS), cell markers, checkpoints assessed. Validation was performed using an independent transcriptome dataset including...
Abstract Immune checkpoint inhibitors (ICI) represent the cornerstone for treatment of patients with metastatic clear cell renal carcinoma (ccRCC). Despite a favorable response subset patients, others experience primary progressive disease, highlighting need to precisely understand plasticity cancer cells and their cross-talk microenvironment better predict therapeutic personalize treatment. Single-cell RNA sequencing ccRCC at different disease stages normal adjacent tissue (NAT) from...
Translocation renal cell carcinomas represent a distinct clinicopathological entity. Studying the natural history, biological behavior and potential prognostic factors are crucially warranted.We selected 54 patients with carcinoma positive nuclear transcription factor E3 EB expression from Juvenile RCC Network. Recurrence-free survival overall were assessed.Median patient age was 24 years (range 1 to 64) male-to-female ratio 1:1.4. At diagnosis 35 (65%) had local disease while 19 (35%)...
Translocation renal cell carcinoma (tRCC) is a rare subtype of kidney cancer involving the TFEB/TFE3 genes. We aimed to investigate genomic and epigenetic features this entity.
Epithelial-mesenchymal transition (EMT) is known to impart metastasis and stemness characteristics in breast cancer. To characterize the epigenetic reprogramming following Twist1-induced EMT, we characterized transcriptome landscapes using whole-genome analysis by RNA-seq, DNA methylation digital restriction enzyme of (DREAM) histone modifications CHIP-seq H3K4me3 H3K27me3 immortalized human mammary epithelial cells relative induced undergo EMT Twist1.EMT accompanied focal hypermethylation...
Objective To describe the management strategies and outcomes of patients with renal medullary carcinoma ( RMC ) characterise predictors overall survival OS ). Patients Methods is a rare aggressive malignancy that afflicts young sickle cell trait; there are limited data on to date. This study who were treated in 2000–2015 at eight academic institutions North America France. The Kaplan–Meier method was used estimate , measured from initial diagnosis date death. Cox regression analysis...
Abstract Human endogenous retroviruses (HERVs), which make up approximately 8% of the human genome, are overexpressed in some breast cancer cells and tissues but without regard to subtype. We, therefore, analyzed TCGA RNA-Seq data evaluate differences expression HERV-K family cancers various subtypes. Four loci on different chromosomes were basal, Her2E, LumA, LumB subtypes 512 patients with invasive ductal carcinoma (IDC). The results for all four showed higher basal subtype, suggesting...
TFE -fusion renal cell carcinomas ( RCCs ) are caused by chromosomal translocations that lead to overexpression of the TFEB and TFE3 genes Kauffman et al., 2014 ). The mechanisms leading kidney tumor development remain uncharacterized effective therapies yet be identified. Hence, need model these diseases in an experimental animal system Here, we show kidney-specific transgenic mice, resulted clear cells, multi-layered basement membranes, severe cystic pathology, ultimately papillary with...
Introduction Long non‐coding RNA (lncRNA) have proven to play key roles in cell physiology from nuclear organization and epigenetic remodeling post‐transcriptional regulation. Last decade, gene expression based‐classifications been developed clear‐cell renal carcinoma (ccRCC) identify distinct subtypes of disease predict patient's outcome. However, there are no current lncRNA comprehensive characterizations ccRCC. Patients methods RNA‐sequencing profiles 475 primary ccRCC samples the Cancer...
Aims Translocation renal cell carcinoma ( tRCC ) is a rare subtype of kidney tumour characterized by translocations involving the transcription factor TFE 3 or TFEB . was introduced into World Health Organization classification in 2004, but much still unknown about natural history, clinicopathological features and outcomes disease. The aim this study to describe landscape fusion transcript large single‐institution series fluorescence in‐situ hybridization FISH )‐confirmed s then compare it...